CN101990534A - 治疗和预防病毒感染 - Google Patents

治疗和预防病毒感染 Download PDF

Info

Publication number
CN101990534A
CN101990534A CN2008801139457A CN200880113945A CN101990534A CN 101990534 A CN101990534 A CN 101990534A CN 2008801139457 A CN2008801139457 A CN 2008801139457A CN 200880113945 A CN200880113945 A CN 200880113945A CN 101990534 A CN101990534 A CN 101990534A
Authority
CN
China
Prior art keywords
substitution
unsubstituted
compound
inhibitor
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801139457A
Other languages
English (en)
Chinese (zh)
Inventor
M·罗
Z·杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of CN101990534A publication Critical patent/CN101990534A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801139457A 2007-11-01 2008-10-31 治疗和预防病毒感染 Pending CN101990534A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US98460107P 2007-11-01 2007-11-01
US60/984601 2007-11-01
US4966508P 2008-05-01 2008-05-01
US61/049665 2008-05-01
PCT/US2008/082140 WO2009059243A1 (en) 2007-11-01 2008-10-31 Treating and preventing viral infections

Publications (1)

Publication Number Publication Date
CN101990534A true CN101990534A (zh) 2011-03-23

Family

ID=40591505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801139457A Pending CN101990534A (zh) 2007-11-01 2008-10-31 治疗和预防病毒感染

Country Status (5)

Country Link
US (1) US8466177B2 (enExample)
EP (1) EP2217573A4 (enExample)
JP (1) JP2011502998A (enExample)
CN (1) CN101990534A (enExample)
WO (1) WO2009059243A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658891A (zh) * 2018-07-03 2018-10-16 河南农业大学 2-硫代噻唑烷-4-酮、衍生物及其制备方法
CN111995622A (zh) * 2020-08-20 2020-11-27 复旦大学 化合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627827A (en) 2010-01-27 2016-02-26 Viiv Healthcare Co Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
CN103402516B (zh) * 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
KR101159000B1 (ko) * 2010-06-18 2012-06-21 (주) 에빅스젠 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 ａｉｄｓ 예방 또는 치료용 약학 조성물
WO2013090405A1 (en) * 2011-12-16 2013-06-20 The J. David Gladstone Institutes Compositions and Methods For Inhibiting Immunodeficiency Virus Transcription
KR101893988B1 (ko) 2018-05-16 2018-08-31 (주)에빅스젠 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345334A (en) * 1967-03-06 1967-10-03 Du Pont Polyureas, poly (diazolidiones), and process for converting polyureas to poly
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
IL106877A (en) * 1992-09-10 1998-03-10 Lilly Co Eli Rhodanine derivatives for use as medicaments for the treatment of alzheimer's disease
DE4331162A1 (de) * 1993-09-14 1995-03-16 Bayer Ag Verfahren zur Herstellung von Cyaninfarbstoffen
US5684024A (en) * 1996-01-25 1997-11-04 Viropharma Incorporated Pyrazole dimers compositions and methods for treating influenza
IL141456A0 (en) * 1998-08-21 2002-03-10 Viropharma Inc Rhodanine derivatives and pharmaceutical compositions containing the same
US20020064736A1 (en) * 2000-09-27 2002-05-30 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and method for producing an azomethine dye
AU2003291613B2 (en) 2002-04-30 2007-09-27 Merck & Co., Inc. Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
DE10348023A1 (de) * 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
WO2005041951A2 (en) 2003-10-28 2005-05-12 Rigel Pharmaceuticals, Inc. Rhodanine derivatives for use as antiviral agents
US20060287319A1 (en) * 2005-06-15 2006-12-21 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658891A (zh) * 2018-07-03 2018-10-16 河南农业大学 2-硫代噻唑烷-4-酮、衍生物及其制备方法
CN108658891B (zh) * 2018-07-03 2020-09-29 河南农业大学 2-硫代噻唑烷-4-酮、衍生物及其制备方法
CN111995622A (zh) * 2020-08-20 2020-11-27 复旦大学 化合物及其用途

Also Published As

Publication number Publication date
US8466177B2 (en) 2013-06-18
US20100286212A1 (en) 2010-11-11
WO2009059243A1 (en) 2009-05-07
JP2011502998A (ja) 2011-01-27
EP2217573A1 (en) 2010-08-18
EP2217573A4 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
JP6804790B1 (ja) Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
EP3498281B1 (en) Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof
TWI625330B (zh) 經取代之多環性吡啶酮衍生物及其前體藥物
CN101990534A (zh) 治疗和预防病毒感染
US12337007B2 (en) Patentiflorin A analogs as antiviral agents
CN103402516B (zh) 用作抗病毒药物的化合物、组合物及使用方法
CN107074880A (zh) 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
Apaydın et al. Design, synthesis and anti-influenza virus activity of furan-substituted spirothiazolidinones
Wang et al. Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1
Botta et al. Multicomponent reactions in the synthesis of antiviral compounds
WO2019147050A1 (ko) 신규한 뉴클레오사이드 또는 뉴클레오타이드 유도체 및 이들의 용도
US12077540B2 (en) Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues
CN107001355A (zh) 吡啶并吡嗪化合物和它们在治疗、改善或预防流感中的用途
Wu et al. Optimization and SAR research at the benzoxazole and tetrazole rings of JNJ4796 as new anti-influenza A virus agents, part 2
WO2013137456A1 (ja) 抗ウイルス組成物
EP3829719B1 (en) Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
Takada et al. Synthesis and antiviral activity of formycin derivatives with anti-influenza virus activity
US11787769B2 (en) Inhibitors of influenza viral entry
CN103694254B (zh) 含磺酰内酯的丁烯内酯类化合物及其合成方法和用途
US10323012B2 (en) Miliusanes as antiviral agents
CN114057635A (zh) 2-芳脲基-n-[2-(2-甲氧基苯氧基)乙基]烟酰胺类化合物及其应用
HK1259624B (en) Anti-influenza polycyclic pyridone derivative and prodrug thereof
Maximova et al. PROGRAM SCHEDULE
EA045093B1 (ru) Производное n4-гидроксицитидина, содержащая его фармацевтическая композиция и связанные с этим противовирусные применения
HK1192249B (en) Ire-1a inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110323